参考文献/References:
[1].Santhanakrishnan R,Wang N,Larson MG,et al. AtriaI fibrillation begets heart failure and vice versa:temporal associations and differences in preserved versus reduced ejection fraction[J]. Circulation,2016,133(5):484-492.
[2].Mulder BA,van Veldhuisen DJ,Crijns HJ,et al. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure:a post-hoc analysis of the RACEⅡstudy[J]. Eur J Heart Fail,2013,15(11):1311-1318．
[3].van Gelder IC,Hagens VE,Bosker HA,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation[J]. N Engl J Med,2002,347(23):1834-1840.
[4].Shelton RJ,Clark AL,Goode K,et al. A randomized,controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure:(CAFE-ⅡStudy)[J]. Heart,2009,95(11):924-930.
[5].中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志,2018,2(4):196-225.
[6].Baruscotti M,Bianco E,Bucchi A,et al. Current understanding of the pathophysiological mechanisms responsible for inappropriate sinus tachycardia:role of the If “funny” current[J]. J Interv Card Electrophysiol,2016,46(1):19-28.
[7].Difrancesco D. Pacemaker mechanisms in cardiac tissue[J]. Annu Rev Physiol,1993,55:455-472.
[8].Difrancesco D. The role of the funny current in pacemaker activity[J]. Circ Res,2010,106 (3):434-446.
[9].Bois P,Bescond J,Renaudon B,et al. Mode of action of bradycardic agent,S16257,on ionic currents of rabbit sinoatrial node cells[J]. Br J Pharmacol,1996,118(4):1051-1057.
[10].Nikolovska Vukadinovi? A,Vukadinovi? D,Borer J,et al. Heart rate and its reduction in chronic heart failure and beyond[J]. Eur J Heart Fail,2017,19(10):1230-1241.
[11].Borer JS,le Heuzey JY. Characterization of the heart rate-lowering action of ivabradine,a selective I(f) current inhibitor[J]. Am J Ther,2008,15(5):461-473.
[12].黄峻. 心力衰竭“易损期”及其心率管理的新认识新理念[J]. 中华心力衰竭和心肌病杂志,2018,2(2):111-113.
[13].Fox K,Ford I,Steg PG,et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction(BEAUTIFUL):a randomised,double-blind,placebo-controlled trial[J]. Lancet,2008,372(9641):807-816.
[14].Swedberg K,Komajda M,B?hm M,et al. Ivabradine and outcomes in chronic heart failure(SHIFT):a randomised placebo-controlled study[J]. Lancet,2010,376(9744):875-885.
[15].Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2022,79(17):e263-e421.
[16].McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
[17].Michels G,Er F,Khan I,et al. Single-channel properties support a potential contribution of hyperpolarization-activated cyclic nucleotide-gated channels and If to cardiac arrhythmias[J]. Circulation,2005,111(4):399-404.
[18].Herrmann S,Layh B,Ludwig A. Novel insights into the distribution of cardiac HCN channels:an expression study in the mouse heart[J]. J Mol Cell Cardiol,2011,51(6):997-1006.
[19].Greener ID,Monfredi O,Inada S,et al. Molecular architecture of the human specialised atrioventricular conduction axis[J]. J Mol Cell Cardiol,2011,50(4):642-651.
[20].Ellinor PT,Lunetta KL,Albert CM,et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation[J]. Nat Genet,2012,44(6):670-675.
[21].den Hoed M,Eijgelsheim M,Esko T,et al. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders [J]. Nat Genet,2013,45(6):621-631.
[22].Verrier RL,Bonatti R,Silva AF,et al. If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation[J]. Heart Rhythm,2014,11(12):2288-2296.
[23].Yamazaki K,Furukawa Y,Nakano H,et al. Inhibition of the subsidiary pacemaker activity by zatebradine,an if inhibitor,in the anesthetized dog heart[J]. J Cardiovasc Pharmacol,1995,26(6):957-964.
[24].王娟. 起搏电流及HCN通道在心房颤动的机制研究及伊伐布雷定对心房颤动的干预研究[D]. 北京协和医学院 ,2015.
[25].黄梦颖. 伊伐布雷定在急性心房颤动中的作用[D]. 西南医科大学,2017.
[26].Ha?ssaguerre M,Ja?s P,Shah DC,et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins[J]. N Engl J Med,1998,339(10):659-666.
[27].Zorn-Pauly K,Schaffer P,Pelzmann B,et al. If in left human atrium:a potential contributor to atrial ectopy[J]. Cardiovasc Res,2004,64(2):250-259.
[28].Li JY,Wang HJ,Xu B,et al. Hyperpolarization activated cation current(I(f)) in cardiac myocytes from pulmonary vein sleeves in the canine with atrial fibrillation[J]. J Geriatr Cardiol,2012,9(4):366-374.
[29].Chen YC,Pan NH,Cheng CC,et al. Heterogeneous expression of potassium currents and pacemaker currents potentially regulates arrhythmogenesis of pulmonary vein cardiomyocytes[J]. J Cardiovasc Electrophysiol,2009,20(9):1039-1045.
[30].甘天翊,汤宝鹏,许国军,等．心脏瓣膜病心房颤动患者心房肌超极化激活环化核苷酸门控通道基因表达的研究[J]. 中华心律失常学杂志,2009,13(4):275-278.
[31].Suenari K,Cheng CC,Chen YC,et al. Effects of ivabradine on the pulmonary vein electrical activity and modulation of pacemaker currents and calcium homeostasis[J]. J Cardiovasc Electrophysiol,2012,23(2):200-206.
[32].Li YD,Ji YT,Zhou XH,et al. Effects of ivabradine on cardiac electrophysiology in dogs with age-related atrial fibrillation[J]. Med Sci Monit,2015,21:1414-1420.
[33].Fox K,Ford I,Steg PG,et al. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine:an analysis from the SIGNIFY study[J]. Eur Heart J,2015,36(46):3291-3296.
[34].Fox K,Komajda M,Ford I,et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction:a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials[J]. Eur Heart J,2013,34(29):2263-2270.
[35].Martin RI,Pogoryelova O,Koref MS,et al. Atrial fibrillation associated with ivabradine treatment:meta-analysis of randomised controlled trials[J]. Heart,2014,100(19):1506-1510.
[36].Tanbo?a ?H,Top?u S,Aksakal E,et al. The risk of atrial fibrillation with ivabradine treatment:a meta-analysis with trial sequential analysis of more than 40000 patients[J]. Clin Cardiol,2016,39(10):615-620.
[37].Cammarano C,Silva M,Comee M,et al. Meta-analysis of ivabradine in patients with stable coronary artery disease with and without left ventricular dysfunction[J]. Clin Ther,2016,38(2):387-395.
[38].Tendera M,Talajic M,Robertson M,et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction(from the BEAUTIFUL Holter Substudy)[J]. Am J Cardiol,2011,107(6):805-811.
[39].Tavazzi L,Swedberg K,Komajda M,et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum:insights from the SHIFT study[J]. Eur J Heart Fail,2013,15(11):1296-1303.
[40].Fox K,Ford I,Steg PG,et al. Ivabradine in stable coronary artery disease without clinical heart failure[J]. N Engl J Med,2014,371(12):1091-1099.
[41].Echahidi N,Pibarot P,O’Hara G,et al. Mechanisms,prevention,and treatment of atrial fibrillation after cardiac surgery[J]. J Am Coll Cardiol,2008,51(8):793-801.
[42].Burashnikov A,Antzelevitch C. Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early after depolarization-induced triggered activity[J]. Circulation,2003,107(18):2355-2360.
[43].Lai LP,Su MJ,Lin JL,et al. Measurement of funny current(I(f)) channel mRNA in human atrial tissue:correlation with left atrial filling pressure and atrial fibrillation[J]. J Cardiovasc Electrophysiol,1999,10(7):947-953.
[44].Marionneau C,Couette B,Liu J,et al. Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart[J]. J Physiol,2005,562(Pt 1):223-234.
[45].El Chemal y A,Magaud C,Patri S,et al. The heart rate-lowering agent ivabradine inhibits the pacemaker current I(f) in human atrial myocytes[J]. J Cardiovasc Electrophysiol,2007,18(11):1190-1196.
[46].Kosiuk J,Oebel S,John S,et al. Ivabradine for rate control in atrial fibrillation[J]. Int J Cardiol,2015,179:27-28.
[47].Wongcharoen W,Ruttanaphol A,Gunaparn S,et al. Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation[J]. Int J Cardiol,2016,224:252-255.
[48].Caminiti G,Fossati C,Rosano G,et al. Addition of ivabradine to betablockers in patients with atrial fibrillation:effects on heart rate and exercise tolerance[J]. Int J Cardiol,2016,202:73-74.
[49].Fontenla A,López-Gil M,Tamargo-Menéndez J,et al. Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project[J]. Rev Esp Cardiol(Engl Ed),2020,73(5):368-375.
[50].Iliuta L,Rac-Albu M. Ivabradine versus beta-blockers in patients with conduction abnormalities or left ventricular dysfunction undergoing cardiac surgery[J]. Cardiol Ther,2014,3(1-2):13-26.
[51].Abdel‐Salam Z,Nammas W. Atrial fibrillation after coronary artery bypass surgery:can ivabradine reduce its occurrence?[J]. J Cardiovasc Electrophysiol,2016,27(6):670-676.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(9):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(9):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(9):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(9):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(9):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(9):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(9):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]